Hyperbaric Oxygen Shows Promise for Long COVID Recovery in Dutch Registry Study
Registry study of 232 long COVID patients finds 56-63% improved after hyperbaric oxygen therapy, but 13-19% worsened.
Summary
A Dutch registry study tracked 232 long COVID patients receiving hyperbaric oxygen therapy (HBOT). After 40 sessions at 2.4-2.5 atmospheres pressure, 56-63% showed clinically meaningful improvement in quality of life scores at 3-month follow-up. However, 13-19% experienced significant deterioration. Cognitive symptoms improved most notably. The treatment involved breathing pure oxygen in pressurized chambers for 90-110 minutes daily over 8 weeks. While promising, the lack of a control group and mixed outcomes highlight the need for more rigorous controlled trials.
Detailed Summary
Long COVID affects 6-12% of adults after SARS-CoV-2 infection, causing persistent fatigue, cognitive problems, and reduced quality of life for months or years. With limited treatment options available, researchers investigated hyperbaric oxygen therapy (HBOT) as a potential intervention.
This prospective registry study followed 232 long COVID patients across six Dutch hyperbaric centers who received off-label HBOT treatment. Patients had persistent cognitive complaints averaging 20 months after initial COVID infection. The treatment protocol involved 40 daily sessions of breathing 100% oxygen in pressurized chambers at 2.4-2.5 atmospheres for 90-110 minutes, delivered over 8 weeks.
At 3-month follow-up, 56-63% of patients showed clinically meaningful improvement (≥10 points) in mental and/or physical component scores on the SF-36 quality of life questionnaire. Cognitive symptoms showed the most improvement. However, 13-19% of patients experienced significant deterioration in these same measures, while the remainder showed no meaningful change.
The study population was predominantly female (70%) with a median age of 42. Most had confirmed COVID infections via PCR testing, and 95% were vaccinated. Only 3% had been hospitalized for their initial COVID infection. At baseline, 43% were unable to work due to long COVID symptoms.
While HBOT appears to help some long COVID patients, the substantial proportion who worsened raises important safety concerns. The mechanism may involve HBOT's effects on tissue oxygenation, stem cell proliferation, anti-inflammatory responses, and neuroplasticity. However, without a control group, it's impossible to determine whether improvements exceed natural recovery rates or represent placebo effects.
Key Findings
- 56-63% of long COVID patients showed clinically meaningful improvement after HBOT
- 13-19% experienced significant deterioration in quality of life measures
- Cognitive symptoms improved more than physical symptoms
- Patients had persistent symptoms averaging 20 months before treatment
- 43% were unable to work due to long COVID at baseline
Methodology
Prospective registry study of 232 patients across six Dutch hyperbaric centers. Patients received 40 sessions of HBOT at 2.4-2.5 atmospheres over 8 weeks. Primary outcomes measured using SF-36 quality of life questionnaire at 3-month follow-up.
Study Limitations
No control group limits ability to distinguish treatment effects from natural recovery. Substantial loss to follow-up at interim timepoints. Single-arm design cannot account for placebo effects or regression to the mean.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.